Phase III trial of Novartis drug Afinitor® met primary endpoint
- Details
- Category: Novartis
Novartis announced today Phase III trial results that showed more than one-third of patients taking Afinitor® (everolimus) tablets* experienced a 50% or greater reduction in the size of their subependymal giant cell astrocytomas (SEGAs), non-cancerous brain tumors associated with tuberous sclerosis complex (TSC)[1],[2],[6].
Pfizer to Explore Strategic Alternatives for its Animal Health and Nutrition Businesses
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) is exploring strategic alternatives for its Animal Health and Nutrition businesses based on its recent business portfolio review to determine the optimal mix of businesses for maximizing shareholder value.
Bristol-Myers Squibb and Innate Pharma Announce Breakthrough Global License Agreement
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) and Innate Pharma S.A. (Euronext Paris: FR0010331421, IPH) announced a global agreement for the development and commercialization of IPH2102, a novel antibody in Phase I development for the treatment of cancer.
Amgen and UCB Team Up with NASA
- Details
- Category: Amgen
Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) are collaborating with the National Aeronautics and Space Administration (NASA) Ames Research Center to conduct a preclinical test of a sclerostin antibody in an experiment that will take place aboard space shuttle Atlantis,
London 2012 partner, GlaxoSmithKline, shares scientific expertise with World Anti-Doping Agency
- Details
- Category: GlaxoSmithKline
London 2012 partner GlaxoSmithKline (GSK) signed a long-term agreement with the World Anti-Doping Agency (WADA) that will help the agency create early detection methods for medicines that have performance-enhancing potential in sport.
Novartis receives FDA approval for Arcapta(TM) Neohaler(TM)
- Details
- Category: Novartis
Novartis announced that the US Food and Drug Administration (FDA) has approved once-daily Arcapta(TM) Neohaler(TM) (indacaterol inhalation powder) 75 mcg for the long-term maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema[1].
Pfizer and ChemRar to Explore Innovative Medical Research and Development Partnership in Russia
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) and the Russian pharmaceutical investment and R&D group ChemRar High Tech Center (ChemRar) have signed a Memorandum of Understanding (MoU) to explore a collaboration focused on research, development and commercialization of innovative drugs in Russia and other countries.
More Pharma News ...
- Bayer advances research in the area of pulmonary hypertension
- AstraZeneca and PTC Therapeutics announce strategic oncology drug discovery collaboration
- Pfizer Files with the FDA for Review of Axitinib for Patients with Advanced Renal Cell Carcinoma
- Bristol-Myers Squibb to Expand Access to Reyataz® in sub-Saharan Africa and India
- Investigational ultra-long-acting insulin degludec reduces hypoglycaemia and improves long-term control
- Bristol-Myers Squibb Foundation Awards $1.5 Million in Grants
- Merck: Regulatory Update on Cladribine Tablets